The pharmaceutical sector over the past year has been dominated by two very different kinds of stories. On one side, you have Eli Lilly (LLY), the undeniable king of the GLP-1 revolution, riding high on the success of Mounjaro and Zepbound. On the other, you have the speculative frenzy surrounding Regencell Bioscience (RGC), a little-known Chinese drugmaker whose stock has skyrocketed an eye-popping 21,000%.
But while the market chases these red-hot names, true value investors are often found sifting through the ashes of fallen giants. Right now, that giant is Pfizer (PFE). Tucked away in a corner, it offers a compelling 6.4% dividend yield and still has a hand to play in the GLP-1 game. With Lilly trading at a lofty 45 times earnings and Regencell’s valuation seemingly detached from any fundamental reality, Pfizer—with a forward P/E of just 8.7—is starting to look like the most rational bet in the room.
There’s no denying Lilly’s achievements. In 2025, Mounjaro sales surged 99%, while Zepbound posted a staggering 175% gain. Together, these two drugs now account for a staggering 56% of the company’s total revenue. They are the undisputed growth engine.
And that is precisely the problem. Lilly is rapidly becoming a one-trick pony. In the pharmaceutical industry, no drug franchise is immune to the inevitable patent cliff. As competition in the GLP-1 space intensifies and generic versions eventually emerge, can Lilly’s current valuation hold? Wall Street’s pricing implies a perfect scenario: sustained dominance and an unassailable throne. At a 45 P/E ratio, there’s little room for error. Any stumble—a clinical setback, tougher competition, or slower-than-expected sales—could trigger significant downside. With a dividend yield of just 0.6%, investors have almost no margin of safety while they wait.
Then there’s Regencell Bioscience. A 21,000% gain is certainly attention-grabbing, but it should serve more as a warning sign than a beacon. A close look at this Chinese drugmaker reveals a fundamental disconnect. It lacks blockbuster products, its pipeline is opaque, and its revenue is negligible. This is the very definition of a speculative mania.
For investors focused on long-term, risk-adjusted returns, chasing Regencell is a dangerous game. While a few may have struck it rich, it’s far more likely that many will be left holding the bag when the music stops. It offers no pipeline depth, no dividend, and no clear path to sustainable growth—just volatility.
In stark contrast to Lilly’s perfection pricing and Regencell’s speculative bubble, Pfizer finds itself in a situation value investors know well: near-term pain, but intact long-term logic and a deeply attractive valuation.
Yes, Pfizer is facing headwinds. Its COVID-19 franchise has collapsed from peak pandemic levels. Over the next few years, several key products, including the blockbuster blood thinner Eliquis, will face patent expirations. These challenges are well-known and, arguably, more than priced into the stock, which has languished as a result.
But beneath the surface, the seeds of a turnaround are being planted:
Eli Lilly is the undisputed champion of the moment, but its stock is priced for a flawless victory. Regencell Bioscience is a speculator’s dream, but its foundation is built on sand.
Pfizer, on the other hand, is a fallen giant navigating a cyclical downturn. It possesses a deep moat, a robust pipeline in development, and a shareholder-friendly management team committed to a high and growing dividend. For investors seeking long-term, risk-adjusted returns, the choice seems clear. While the crowd chases momentum in Lilly and Regencell, the real value may lie in the unloved pharma giant waiting in the wings. As market sentiment eventually normalizes and Pfizer’s pipeline advances, this forgotten behemoth has the potential to once again earn Wall Street’s favor. And while investors wait for that turnaround, they’ll be paid a handsome 6.4% dividend to stay the course.
